📌 Key Takeaways
- On May 15, 2026, Santen Pharmaceutical launched Japan’s first acquired blepharoptosis (ptosis) eye drop, Upneeq® Mini 0.1% —
six years after the FDA approved the same drug in the U.S. under the brand name Upneeq®. - Active ingredient: oxymetazoline HCl. Eyelid elevation begins within 5–15 minutes and lasts up to 8 hours.
Over 80% of users showed measurable lid lift in clinical trials (AAO 2025 report). - Prescription-only, out-of-pocket (no insurance coverage).
The package insert explicitly states: “Not recommended for cosmetic use in healthy individuals.”
A 2026 FAERS analysis identified new safety signals not visible in pre-approval trials.
“My eyelids feel heavy.” “My eyes look smaller than they used to.” “I get headaches by evening.” —
These are common complaints among people with acquired ptosis
who have hesitated to pursue surgical correction.
On May 15, 2026, a new option arrived.
Santen Pharmaceutical launched Upneeq® Mini Ophthalmic Solution 0.1% —
Japan’s first prescription eye drop approved to treat acquired blepharoptosis.
One drop per day. No surgery required.
INDEX
What Is Upneeq? The Basics
Generic name: Oxymetazoline hydrochloride
Manufacturer: Santen Pharmaceutical Co., Ltd.
Japan approval date: December 22, 2025
Japan launch date: May 15, 2026
Indication: Acquired blepharoptosis (drooping eyelid)
Dosage: 1 drop, once daily (single-use vial, 0.3 mL)
Insurance coverage: None — out-of-pocket only (self-pay)
The same molecule was FDA-approved in the U.S. in 2020 under the brand name Upneeq®.
Japan’s approval came approximately six years later.
How Does It Lift the Eyelid?
To understand how Upneeq works,
it helps to know that two distinct muscles control upper eyelid position.
🔬 Two Muscles That Raise the Eyelid — and Upneeq’s Target
Levator palpebrae superioris:
The primary muscle responsible for voluntary eyelid elevation.
Age-related laxity of its aponeurosis is the most common cause of acquired ptosis
(aponeurotic blepharoptosis).
Müller’s muscle:
A sympathetically innervated accessory muscle.
This is Upneeq’s target.
Oxymetazoline stimulates α1-adrenergic receptors,
causing Müller’s muscle to contract and physically raise the lid.
Oxymetazoline is the same active ingredient found in over-the-counter nasal decongestants (e.g., Afrin).
In nasal sprays, it constricts blood vessels in the nasal mucosa to relieve congestion.
Reformulated as an ophthalmic solution, it targets the smooth muscle of the eyelid instead.
Efficacy Data: What the Evidence Shows
(AAO Ophthalmic Technology Assessment, 2025)
Japan trial: approximately 0.59 mm greater improvement vs. placebo
One millimeter may sound modest — but in ophthalmology, 1 mm is clinically significant.
The diagnostic threshold for ptosis is a margin reflex distance (MRD1) below 4 mm.
A 1 mm lift produces a measurable change in both visual field and facial appearance.
Ptosis is classified as congenital or acquired.
Upneeq is indicated only for the acquired form.
Common causes of acquired ptosis:
· Age-related aponeurotic ptosis (most common — levator aponeurosis laxity)
· Long-term contact lens wear (especially rigid gas-permeable lenses)
· Post-Botox temporary ptosis (off-label context)
· Neurological conditions: myasthenia gravis, Horner syndrome, oculomotor nerve palsy
Important: Sudden-onset ptosis can signal a cerebral aneurysm,
oculomotor nerve palsy, or other emergencies.
Seeking Upneeq without a proper neurological and ophthalmological evaluation
carries serious risk.
Safety Profile: What to Watch For
⚠️ Adverse Effects Listed in the Japanese Package Insert (PMDA)
Eyelid pruritus (itching) · conjunctival hyperemia · punctate keratitis ·
blurred vision · conjunctival edema · eyelid eczema · visual disturbance ·
elevated blood pressure · decreased heart rate
In clinical trials, adverse events were observed in 1–5% of patients.
Serious adverse event rates: 1.2% (drug) vs. 1.6% (placebo) —
no statistically significant difference (FDA Summary).
⚠️ Two Risks That Require Special Attention
① Mydriasis (pupil dilation)
Müller’s muscle contraction can also stimulate the iris dilator muscle,
causing pupil dilation.
This may increase light sensitivity and impair driving in low-light conditions.
Contraindicated in narrow-angle glaucoma:
mydriasis can trigger acute angle-closure and a dangerous spike in intraocular pressure.
② Rebound and tolerance risk
The AAO notes that oxymetazoline — like its nasal decongestant counterpart —
“may cause rebound congestion, dependence, and diminishing effect over time”
(Review of Optometry, 2025).
Discontinuation returns the eyelid to its baseline state.
Long-term tolerance data remain limited and are still being studied.
⚠️ Post-Market Safety Signals: FAERS Analysis (April 2026)
In April 2026, researchers published an analysis of the FDA Adverse Event Reporting System (FAERS)
covering July 2020 through April 2025 — thousands of real-world cases.
The study identified new safety signals not captured in pre-approval trials.
The authors described the findings as containing “both reassuring and cautionary elements.”
Full peer-reviewed details are forthcoming (Review of Optometry, April 10, 2026).
This is not unique to Upneeq.
Any drug approved on 6-week trial data will reveal new patterns
when used by a broader population over years.
It underscores the importance of post-market surveillance for all approved therapeutics.
Pricing and Access in Japan
Available at ophthalmology clinics, aesthetic dermatology, and cosmetic surgery practices.
30 vials (30-day supply): approx. ¥5,980–6,000 JPY
~¥200–300 per vial (varies by clinic; consultation fees may apply separately)
The Cosmetic Use Question: Where the Line Is Drawn
Part of Upneeq’s buzz stems from the blurring boundary
between ophthalmological treatment and cosmetic desire.
📋 Treatment vs. Cosmetic Use: Where Upneeq Stands
Approved use: Treatment of acquired blepharoptosis.
Prescription by an ophthalmologist following a confirmed clinical diagnosis.
Package insert (Santen):
“Use for cosmetic purposes in healthy individuals is not recommended.”
Gray zone: Non-ophthalmology clinics diagnosing “acquired ptosis”
based on subjective complaints like “my eyes look smaller” —
without formal ophthalmological assessment.
Technically within physician discretion, but carries diagnostic risk.
Critical warning: Sudden-onset ptosis may be a sign of
cerebral aneurysm, oculomotor nerve palsy, Horner syndrome, or myasthenia gravis.
Treating these cases with Upneeq without ruling out neurological causes
risks delaying diagnosis of a life-threatening condition.
For Clinicians: Off-Label Use After Botox
In the U.S., Upneeq has been used off-label as a “bridge treatment”
for temporary eyelid ptosis following glabellar or forehead Botox injections.
Related studies are registered on ClinicalTrials.gov,
and the drug has gained traction in aesthetic medicine settings.
In Japan, this remains an off-label application.
Prescribing Upneeq for post-Botox ptosis requires explicit informed consent,
clear disclosure of off-label status, and physician judgment —
with no insurance coverage applicable.
Upneeq’s arrival genuinely expands the treatment landscape for acquired ptosis.
But as “no surgery, just drops” messaging spreads,
there is a real risk of missing cases where drooping eyelids are not a cosmetic issue —
but an early sign of an aneurysm.
The right first step is not a prescription.
It is a proper evaluation by an ophthalmologist or neurosurgeon.
“No surgery” expands your options.
“No diagnosis” eliminates them.
Summary
- May 15, 2026: Santen Pharmaceutical launched Upneeq® Mini 0.1% —
Japan’s first prescription eye drop for acquired blepharoptosis,
approximately six years after FDA approval in the U.S. (2020). - Onset within 5–15 minutes, duration up to 8 hours.
80%+ efficacy rate, 88% patient satisfaction (AAO 2025).
Average lid elevation: ~1 mm. - Contraindicated in narrow-angle glaucoma (risk of acute angle-closure).
Additional risks: mydriasis, rebound, long-term tolerance.
April 2026 FAERS analysis flagged new post-market safety signals. - Package insert states: “Not recommended for cosmetic use in healthy individuals.”
Sudden-onset ptosis may indicate a neurological emergency —
ophthalmological and neurological evaluation must precede any prescription.
Frequently Asked Questions
However, proper diagnosis of acquired ptosis and exclusion of neurological causes
(aneurysm, nerve palsy, etc.) require ophthalmological and neurological assessment.
NERO recommends starting with an ophthalmologist or neurosurgeon
to confirm the underlying cause before seeking a prescription.
it temporarily stimulates Müller’s muscle to lift the lid while the drug is active.
Discontinuation returns the eyelid to its baseline state.
Permanent correction requires surgery.
Long-term rebound and tolerance effects are still under study.
and not reinserted for at least 15 minutes afterward.
The vasoconstricting properties of oxymetazoline may affect lens material.
This applies to both soft and rigid gas-permeable lenses.
While real-world use for post-Botox ptosis exists in the U.S.,
any such prescription in Japan requires explicit informed consent,
disclosure of off-label status, and physician judgment.
Self-administration without a prescription is not appropriate.
Sources:
Santen Pharmaceutical — “Upneeq® Mini Ophthalmic Solution 0.1%: Domestic Manufacturing and Marketing Approval Obtained,” December 22, 2025 /
Santen Pharmaceutical — “Upneeq® Mini Ophthalmic Solution 0.1% Launch Announcement,” April 1, 2026 /
Upneeq® Mini Ophthalmic Solution 0.1% Package Insert (March 2026, 2nd revision), Santen Pharmaceutical Co., Ltd. /
Bacharach J et al. “Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results.” Clinical Ophthalmology, 2021 /
American Academy of Ophthalmology — “Ophthalmic Technology Assessment: Adrenergic Agents for Acquired Ptosis,” 2025 /
Review of Optometry — “Study Reveals New Safety Signals of Oxymetazoline Eye Drops for Blepharoptosis,” April 10, 2026 /
Review of Optometry — “AAO Report Concludes Oxymetazoline Effectively Treats Ptosis Short-term,” 2025 /
EyeWiki (American Academy of Ophthalmology) — “Oxymetazoline,” last updated December 10, 2025 /
Nikkei Medical Prescription Drug Dictionary — “Upneeq Mini Ophthalmic Solution 0.1%,” updated April 17, 2026
